COVID-19

Excerpt from the article: The coronavirus has hit Black communities across the U.S. so hard that the numbers have stopped doctors in their tracks. In Philadelphia, where 42% of the population is Black and 41% is white, Black people are nearly three times more likely than white people to have the coronavirus. An appalling 52% of COVID-19 deaths in…

Excerpt from the Press Release: Kaiser Permanente has joined a Phase 3 clinical trial to test a coronavirus vaccine candidate currently in production by Pfizer and BioNTech, and will seek to enroll 1,400 adults aged 18-85 in California and Oregon to join in the study, a press release from the medical organization states. The aim…

Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Quidel Corporation (NASDAQ: QDEL) (“Quidel”),a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received Health Canada authorization to market and sell the Lyra® Direct SARS-CoV-2 Assay in Canada. (IO315563, COVID-19 Medical Device Authorization for Importation or Sale; 07/20/2020)…

Excerpt from the Article: PHILADELPHIA, Aug. 13, 2020 /PRNewswire/ — When the COVID-19 pandemic began earlier this year, doctors and researchers at Children’s Hospital of Philadelphia (CHOP) rapidly pivoted to focus on defeating the novel virus. Across the hospital, members of the CHOP team – from infectious disease researchers to population health experts – mobilized…

Excerpt from the Press Release: SAN DIEGO, Aug. 14, 2020 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that in response to Adamis’ Pre-Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA), the FDA has provided detailed comments regarding the prospective use of Tempol in a randomized placebo…

Excerpt from the Press Release: OTTAWA, Ontario & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Variation Biotechnologies Inc., an Ottawa-based wholly-owned Canadian subsidiary of VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has been awarded up to a CAD$56 million contribution from the Strategic Innovation Fund of…

Excerpt from the Press Release: SAN DIEGO, Aug. 6, 2020 /PRNewswire/ — Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, and Aegea Biotechnologies, Inc., an innovative private life science company with an extensive portfolio of issued patents…

Excerpt from the Press Release: Burlingame, CA, August 10, 2020 – Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced that the Brazilian regulatory agency, Anvisa, has granted permission to commence a Phase…

Excerpt from the article: Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising. GIGA-2050, a new class of drug called a recombinant hyperimmune, offers 100-fold higher potency than convalescent serum therapy. “GIGA-2050 is a mix of 12,500 different antibody sequences…